Aarti Drugs Ltd
AARTIDRUGSAarti Drugs Ltd
AARTIDRUGS


Price Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
24.89 | 2.96 | 0.24% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.09 | 6.50 | 0.52% |
Forecast & Ratings
Detailed Forecast from 1 analyst
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Aarti Drugs Limited is a pharmaceutical company offering active pharmaceutical ingredients (APIs) in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antifungals, antibiotic, antidiabetic, sedative and vitamins.
Investor Presentation
View olderÂPeers
Compare with peersÂGet more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 1,139.84 | 1,199.17 | 1,244.68 | 1,567.12 | 1,812.04 | 2,162.57 | 2,499.97 | 2,718.24 | 2,532.61 | 2,345.83 | ||||||||||
Raw Materials | 758.16 | 765.89 | 821.92 | 1,026.31 | 1,210.60 | 1,310.66 | 1,750.06 | 1,863.71 | 1,626.10 | 2,050.72 | ||||||||||
Power & Fuel Cost | 53.93 | 59.42 | 71.42 | 84.39 | 103.83 | 98.20 | 128.34 | 156.10 | 154.31 | |||||||||||
Employee Cost | 40.19 | 47.95 | 52.14 | 54.55 | 61.35 | 65.88 | 69.30 | 80.43 | 90.60 | |||||||||||
Selling & Administrative Expenses | 37.92 | 41.74 | 47.60 | 54.66 | 80.16 | 98.43 | 104.24 | 104.66 | 95.12 | |||||||||||
Operating & Other expenses | 69.83 | 89.69 | 48.68 | 130.12 | 84.63 | 144.28 | 104.11 | 201.71 | 241.61 | |||||||||||
EBITDA | 179.81 | 194.48 | 202.92 | 217.09 | 271.47 | 445.12 | 343.92 | 311.63 | 324.87 | 295.11 | ||||||||||
Depreciation/Amortization | 36.53 | 38.46 | 40.06 | 42.56 | 48.75 | 49.88 | 50.05 | 50.32 | 51.45 | 54.48 | ||||||||||
PBIT | 143.28 | 156.02 | 162.86 | 174.53 | 222.72 | 395.24 | 293.87 | 261.31 | 273.42 | 240.63 | ||||||||||
Interest & Other Items | 48.02 | 40.02 | 38.36 | 43.51 | 37.42 | 26.23 | 23.91 | 37.14 | 37.89 | 35.84 | ||||||||||
PBT | 95.26 | 116.00 | 124.50 | 131.02 | 185.30 | 369.01 | 269.96 | 224.17 | 235.53 | 204.79 | ||||||||||
Taxes & Other Items | 26.55 | 34.21 | 42.20 | 41.27 | 43.89 | 88.60 | 64.92 | 57.88 | 64.10 | 52.12 | ||||||||||
Net Income | 68.71 | 81.79 | 82.30 | 89.75 | 141.41 | 280.41 | 205.04 | 166.29 | 171.43 | 152.67 | ||||||||||
EPS | 7.09 | 8.51 | 8.67 | 9.51 | 15.08 | 30.09 | 22.07 | 17.96 | 18.58 | 16.61 | ||||||||||
DPS | 1.69 | 0.25 | 0.25 | 0.25 | 0.50 | 2.50 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||||
Payout ratio | 0.24 | 0.03 | 0.03 | 0.03 | 0.03 | 0.08 | 0.05 | 0.06 | 0.05 | 0.06 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Aarti Drugs Ltd | 22.16 | 2.96 | 0.24% |
Sun Pharmaceutical Industries Ltd | 43.84 | 6.26 | 0.77% |
Cipla Ltd | 28.85 | 4.44 | 0.88% |
Torrent Pharmaceuticals Ltd | 66.58 | 16.09 | 0.86% |
Price Comparison
Compare AARTIDRUGS with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 1.53%
Top 5 Mutual Funds holding Aarti Drugs Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 6.0976% | Percentage of the fund’s portfolio invested in the stock 1.39% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 26/78 (+1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3625% | Percentage of the fund’s portfolio invested in the stock 0.97% | Change in the portfolio weight of the stock over the last 3 months 0.71% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 30/50 (+6) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9794% | Percentage of the fund’s portfolio invested in the stock 1.11% | Change in the portfolio weight of the stock over the last 3 months -0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 24/33 (-3) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
AARTIDRUGS has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.24%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.42 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateFeb 4, 2025
Dividend/Share
₹1.00
Ex DateEx Date
Feb 4, 2025
Cash Dividend
Ex DateEx DateFeb 6, 2024
Dividend/Share
₹1.00
Ex DateEx Date
Feb 6, 2024
Cash Dividend
Ex DateEx DateFeb 8, 2023
Dividend/Share
₹1.00
Ex DateEx Date
Feb 8, 2023
Cash Dividend
Ex DateEx DateFeb 9, 2022
Dividend/Share
₹1.00
Ex DateEx Date
Feb 9, 2022
Cash Dividend
Ex DateEx DateNov 3, 2020
Dividend/Share
₹2.50
Ex DateEx Date
Nov 3, 2020
Aarti Drugs has received reaffirmation in credit rating at ICRA AA-; Stable/ ICRA A1+ for bank facilities aggregating Rs 1452.8 crore. Powered by Capital Market - Live
Revenue from operations declined 6.44% to Rs 568.50 crore in third quarter of FY25 as compared with Rs 607.61 crore posted same period a year ago. Profit before tax shed 1.53% to Rs 50.76 crore in the third quarter of FY25 as against Rs 51.55 crore recorded in the same quarter last year. EBITDA stood at Rs 62.3 crore in Q3 of FY25, down 13% from Rs 71.8 crore posted in the December 2023 quarter. EBITDA Margin to 11.2% in Q3 FY25 as against with 11.8% posted in Q3 FY24. During the quarter, revenue from API segment declined 5.2% YoY to Rs 460 crore, formulation business dropped 39.4% YoY to Rs 48 crore while specialty chemicals increased 7.6% YoY to Rs 33.8 crore and intermediaries & others jumped 46.3% YoY to Rs 14.8 crore while in Q3 FY25. On standalone basis, the company's net profit increased 21.85% to Rs 38.53 crore in Q3 FY25 as compared with Rs 31.62 crore in Q3 FY24. Revenue stood at Rs 525.91 crore in December 2024 quartre, down 2.58% YoY. The standalone business contributed approximately 91% to the consolidated revenue for the quarter. Around 64% of the revenues came from the domestic market and 36% from the exports market for third quarter of FY25 for a standalone business. Within the API business, the antibiotic therapeutic category contributed around 38.6%, anti-diabetic approximately 16.1%, anti-protozoal around 16.5%, anti-inflammatory approximately 11.9%, antifungal around 12% and the rest contributed approximately 5% to total API sales for Q3 FY25. Meanwhile, the company's board has declared an interim dividend of Re 1 per equity share for the financial year 2023-24. The record date for the purpose of payment of interim dividend has been fixed as 4 February 2025. Adhish Patil, CFO & COO, Aarti Drugs, said, 'This quarter has presented significant challenges for our API segment, with both revenue and profit declining on a year-on-year basis. This is mainly due to reduced market prices and weaker demand. Although prices remained stable during the December quarter, there was a negative price variance when compared to the same period last year. Formulation segment revenue stood at Rs. 48.6 crores for the quarter, with an export contribution of 47% whereas in 9M FY25 revenue stood at Rs 186.9 crores. The greenfield project at Sayakha, Gujarat for Speciality Chemicals will commence trial production in this quarter. With this, the operating leverage is expected to kick in from the subsequent quarter with improved capacity utilization. There had been certain teething issues in Tarapur greenfield project, which are sorted now and we expect to ramp up the production to 500+ tonnes per month by the end of March'25. In total we will have sequential ramp up of capacity to 1,600 tonnes per month by end of FY26. During 9M FY25, the company has incurred capex of approximately Rs 136 crore mainly towards capacity expansion, backward integration and new product launches. We anticipate a total capex of around Rs 200 crore for the full year. This capex would we mainly through internal accruals and partly through term loans. Despite facing these short-term challenges, we are staying focused on our long-term goals. We are confident about achieving double digit growth in revenues with EBITDA Margins of 13%-14% in FY26 which is a healthy indicator of our financial stability and operational efficiency. Despite API pricing pressures, driven by fluctuating raw material costs, heightened competition, and regulatory demands in global markets we remain committed to achieving growth and profitability by enhancing operational efficiencies and expanding our market presence. We are dedicated to tackling these challenges and emerging stronger in the future.' Aarti Drugs forms part of $6 Billion Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Speciality Chemicals and produces Formulations with its whollyowned subsidiary-Pinnacle Life Science Private. Powered by Capital Market - Live
Aarti Drugs has fixed 04 February 2025 as record date for purpose of interim dividend of Re 1 per equity share of Rs 10 each for FY 2024-25. Powered by Capital Market - Live
Net profit of Aarti Drugs rose 1.04% to Rs 37.05 crore in the quarter ended December 2024 as against Rs 36.67 crore during the previous quarter ended December 2023. Sales declined 8.14% to Rs 556.60 crore in the quarter ended December 2024 as against Rs 605.94 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales556.60605.94 -8 OPM %11.0911.58 - PBDT64.5564.21 1 PBT50.7551.55 -2 NP37.0536.67 1 Powered by Capital Market - Live
Net profit of Aarti Drugs rose 21.85% to Rs 38.53 crore in the quarter ended December 2024 as against Rs 31.62 crore during the previous quarter ended December 2023. Sales declined 4.40% to Rs 514.54 crore in the quarter ended December 2024 as against Rs 538.21 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales514.54538.21 -4 OPM %11.7111.10 - PBDT64.0554.67 17 PBT52.0342.87 21 NP38.5331.62 22 Powered by Capital Market - Live
Aarti Drugs announced that the Board of Directors of the Company at its meeting held on 29 January 2025, has recommended a Interim dividend of Rs.1 per share (i.e.10%), subject to the approval of the shareholders.Powered by Capital Market - Live
Aarti Drugs will hold a meeting of the Board of Directors of the Company on 29 January 2025.Powered by Capital Market - Live
USFDA has determined that the inspection classification of this facility is voluntary action indicated (VAI). Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP). Due to this company can export the products such as Ciprofloxacin HCl API, Zolpidem Tartrate API, Raloxifene HCl API, Celecoxib API and Niacin API in US Market. USFDA had inspected the company's API manufacturing facility at Plot No-E-22, MIDC, Tarapur, Maharashtra from 12th to 20th September 2024. Aarti Drugs is primarily involved in manufacturing and marketing of Active Pharmaceutical Ingredients (API), Pharma Intermediates and Specialty Chemicals. The company's consolidated net profit dropped 11.6% to Rs 35.01 crore on 6.7% decline in net sales to Rs 598.33 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live
Aarti Drugs has received Establishment Inspection Report (EIR) from USFDA concluding the inspection as closed for its API manufacturing facility located at Plot No-E-22, MIDC, Tarapur, Maharashtra. UFDA has determined that the inspection classification of this facility is 'voluntary action indicated' (VAI). Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP). Powered by Capital Market - Live
Net profit of Aarti Drugs declined 11.57% to Rs 35.01 crore in the quarter ended September 2024 as against Rs 39.59 crore during the previous quarter ended September 2023. Sales declined 6.74% to Rs 598.33 crore in the quarter ended September 2024 as against Rs 641.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales598.33641.54 -7 OPM %11.2111.92 - PBDT59.6068.88 -13 PBT45.8856.27 -18 NP35.0139.59 -12 Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 10.08%, vs industry avg of 9.04%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.71% to 0.67%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 13.82%, vs industry avg of 15.28%